## Isabel Santana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6278712/publications.pdf

Version: 2024-02-01

199 9,448 48
papers citations h-index

48 88
h-index g-index

48315

210 210 docs citations

210 times ranked 13324 citing authors

#	Article	IF	CITATIONS
1	Toulouse-Piéron Cancellation Test: Normative scores for the portuguese population. Applied Neuropsychology Adult, 2023, 30, 169-175.	1.2	8
2	Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. Brain, 2023, 146, 321-336.	7.6	30
3	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Applied Neuropsychology Adult, 2022, 29, 112-119.	1.2	18
4	Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases. Brain, 2022, 145, 700-712.	7.6	16
5	Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 336-339.	1.9	1
6	Serum neurofilament light chain as a surrogate of cognitive decline in sporadic and familial frontotemporal dementia. European Journal of Neurology, 2022, 29, 36-46.	3.3	14
7	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	7.6	27
8	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp> : A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	<b>5.</b> 3	21
9	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	6.2	4
10	The European Portuguese version of the Oxford Cognitive Screening (OCS-Pt): a screening test for acute stroke patients. Neurological Sciences, 2022, 43, 3717-3728.	1.9	2
11	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. Journal of Alzheimer's Disease, 2022, , 1-14.	2.6	3
12	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
13	The Road to Personalized Medicine in Alzheimer's Disease: The Use of Artificial Intelligence. Biomedicines, 2022, 10, 315.	3.2	15
14	Plasma Lipocalin 2 in Alzheimer's disease: potential utility in the differential diagnosis and relationship with other biomarkers. Alzheimer's Research and Therapy, 2022, 14, 9.	6.2	2
15	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	2.4	2
16	Dataâ€driven staging of genetic frontotemporal dementia using multiâ€modal <scp>MRI</scp> . Human Brain Mapping, 2022, 43, 1821-1835.	3.6	7
17	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	3.1	1
18	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. Journal of Neurology, 2022, 269, 4322-4332.	3.6	1

#	Article	IF	CITATIONS
19	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	3.7	1
20	Lewy body dementia is associated with an increased risk of atrial fibrillation: A case-control study. Journal of Clinical Neuroscience, 2022, 99, 62-65.	1.5	2
21	Cytogenomic Analysis of Long-Term Epilepsy-Associated Tumors Using an Array-Based CGH Strategy. Cytogenetic and Genome Research, 2022, 162, 28-33.	1.1	0
22	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. Neurology, 2022, 99, .	1.1	5
23	Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 659-667.	1.9	21
24	Neuropsychological profile of amyloidâ€positive versus amyloidâ€negative amnestic Mild Cognitive Impairment. Journal of Neuropsychology, 2021, 15, 41-52.	1.4	11
25	Estimates of Geriatric Delirium Frequency in Noncardiac Surgeries and Its Evaluation Across the Years: A Systematic Review and Meta-Analysis. Journal of the American Medical Directors Association, 2021, 22, 613-620.e9.	2.5	20
26	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.8	36
27	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimer's and Dementia, 2021, 17, 969-983.	0.8	31
28	Biomarker counseling, disclosure of diagnosis and followâ€up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. International Journal of Geriatric Psychiatry, 2021, 36, 324-333.	2.7	19
29	Neuropsychological features of progranulin-associated frontotemporal dementia: a nested case-control study. Neural Regeneration Research, 2021, 16, 910.	3.0	3
30	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	5.9	42
31	Protective effects of cognitive and brain reserve in multiple sclerosis: Differential roles on social cognition and †classic cognitionâ€. Multiple Sclerosis and Related Disorders, 2021, 48, 102716.	2.0	1
32	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
33	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 608-616.	1.9	10
34	PHACTR1 genetic variability is not critical in small vessel ischemic disease patients and PcomA recruitment in C57BL/6J mice. Scientific Reports, 2021, 11, 6072.	3.3	2
35	Investigating the Spatial Associations Between Amyloid-β Deposition, Grey Matter Volume, and Neuroinflammation in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 80, 113-132.	2.6	12
36	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	6.2	12

#	Article	IF	Citations
37	Outcomes on Social and Classic Cognition in adults with Pediatric-onset Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2021, 53, 103071.	2.0	1
38	Knowing how to do it or doing it? A double dissociation between tool-gesture production and tool-gesture knowledge. Cortex, 2021, 141, 449-464.	2.4	4
39	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. Neurobiology of Aging, 2021, 108, 155-167.	3.1	3
40	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	2.7	28
41	Disease-related cortical thinning in presymptomatic granulin mutation carriers. Neurolmage: Clinical, 2021, 29, 102540.	2.7	8
42	Early-onset phenotype of bi-allelic <i>GRN</i> mutations. Brain, 2021, 144, e22-e22.	7.6	5
43	Combined Structural MR and Diffusion Tensor Imaging Classify the Presence of Alzheimer's Disease With the Same Performance as MR Combined With Amyloid Positron Emission Tomography: A Data Integration Approach. Frontiers in Neuroscience, 2021, 15, 638175.	2.8	5
44	Differential synaptic marker involvement in the different genetic forms of frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, .	0.8	1
45	Cognitive Trajectories Following Acute Infection in Older Patients With and Without Cognitive Impairment: An 1-Year Follow-Up Study. Frontiers in Psychiatry, 2021, 12, 754489.	2.6	1
46	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
47	Single Word Repetition Predicts Long-Term Outcome of Aphasia Caused by an Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104566.	1.6	5
48	APOE É>4-TOMM40L Haplotype Increases the Risk of Mild Cognitive Impairment Conversion to Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 78, 587-601.	2.6	0
49	CYLD variants in frontotemporal dementia associated with severe memory impairment in a Portuguese cohort. Brain, 2020, 143, e67-e67.	7.6	16
50	Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2020, 21, 8680.	4.1	13
51	Patients with progranulin mutations overlap with the progressive dysexecutive syndrome: towards the definition of a frontoparietal dementia phenotype. Brain Communications, 2020, 2, fcaa126.	3.3	3
52	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 975-984.	1.9	25
53	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in <i>C9orf72</i> expansion carriers in the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1325-1328.	1.9	12
54	Incidental findings in peer neurological examination. Journal of the Neurological Sciences, 2020, 417, 117065.	0.6	0

#	Article	IF	CITATIONS
55	Face-Specific Perceptual Distortions Reveal A View- and Orientation-Independent Face Template. Current Biology, 2020, 30, 4071-4077.e4.	3.9	15
56	The Retinal Inner Plexiform Synaptic Layer Mirrors Grey Matter Thickness of Primary Visual Cortex with Increased Amyloid <i>β</i> Load in Early Alzheimer's Disease. Neural Plasticity, 2020, 2020, 1-11.	2.2	13
57	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. Brain Communications, 2020, 2, .	3.3	20
58	A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid $\hat{l}^2$ -amyloid42, total-tau, phospho-tau and $\hat{l}_\pm$ -synuclein in the differential diagnosis of neurodegenerative dementia. Journal of Neurology, 2020, 267, 2567-2581.	3.6	6
59	C-reactive protein as a predictor of mild cognitive impairment conversion into Alzheimer's disease dementia. Experimental Gerontology, 2020, 138, 111004.	2.8	18
60	Neuropsychological Contribution to Predict Conversion to Dementia in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 74, 785-796.	2.6	6
61	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	1.9	106
62	Alzheimer's Disease Genetics: Review of Novel Loci Associated with Disease. Current Genetic Medicine Reports, 2020, 8, 1-16.	1.9	20
63	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 612-621.	1.9	55
64	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic <i>C9orf72</i> Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	5.3	19
65	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	2.4	26
66	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. Nature Communications, 2020, 11, 619.	12.8	67
67	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	5.2	27
68	Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases. Molecular Neurobiology, 2019, 56, 2811-2821.	4.0	20
69	Increased CSF tau is associated with a higher risk of seizures in patients with Alzheimer's disease. Epilepsy and Behavior, 2019, 98, 207-209.	1.7	22
70	Interplay Between Macular Retinal Changes and White Matter Integrity in Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 70, 723-732.	2.6	11
71	Can Subjective Memory Complaints Identify $\hat{Al^2}$ Positive and $\hat{Al^2}$ Negative Amnestic Mild Cognitive Impairment Patients?. Journal of Alzheimer's Disease, 2019, 70, 1103-1111.	2.6	4
72	Lower CSF Amyloid-Beta1–42 Predicts a Higher Mortality Rate in Frontotemporal Dementia. Diagnostics, 2019, 9, 162.	2.6	3

#	Article	IF	CITATIONS
73	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	10.2	128
74	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	10.2	85
75	Association between Adipokines and Biomarkers of Alzheimer's Disease: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2019, 67, 725-735.	2.6	18
76	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. Neurolmage, 2019, 189, 645-654.	4.2	33
77	Retinal texture biomarkers may help to discriminate between Alzheimer's, Parkinson's, and healthy controls. PLoS ONE, 2019, 14, e0218826.	2.5	54
78	Education modulates brain maintenance in presymptomatic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1124-1130.	1.9	23
79	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.8	82
80	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	4.4	29
81	Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 91.	6.2	78
82	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	2.7	27
83	Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients. Biomolecules, 2019, 9, 800.	4.0	8
84	Discriminative capacity and construct validity of the Clock Drawing Test in Mild Cognitive Impairment and Alzheimer's disease. Clinical Neuropsychologist, 2019, 33, 1159-1174.	2.3	5
85	Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 2.	6.2	19
86	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	3.1	13
87	Adiponectin and sporadic Alzheimer's disease: Clinical and molecular links. Frontiers in Neuroendocrinology, 2019, 52, 1-11.	5.2	25
88	Clock drawing test in mild cognitive impairment: Correlation with cerebral perfusion in single-photon emission computed tomography Neuropsychology, 2019, 33, 617-632.	1.3	10
89	Advanced MRI study of migrainous infarction presenting as cortical laminar necrosis – Case report and literature review. Clinical Neurology and Neurosurgery, 2018, 167, 82-85.	1.4	8
90	Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimer's and Dementia, 2018, 14, 751-763.	0.8	61

#	Article	IF	Citations
91	Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 61, 1097-1105.	2.6	7
92	Theory of Mind and Executive Functions are Dissociated in Multiple Sclerosis. Archives of Clinical Neuropsychology, 2018, 33, 541-551.	0.5	24
93	Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration. Journal of Alzheimer's Disease, 2018, 64, S647-S657.	2.6	10
94	Prevalence of the apolipoprotein E $\hat{l}\mu$ 4 allele in amyloid $\hat{l}^2$ positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
95	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. Neurobiology of Aging, 2018, 66, 181.e3-181.e10.	3.1	19
96	Validation study of the Alzheimer's disease assessment scale–cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimer's disease. Clinical Neuropsychologist, 2018, 32, 46-59.	2.3	24
97	The Montreal Cognitive Assessment (MoCA) as a screening test for cognitive dysfunction in multiple sclerosis. Applied Neuropsychology Adult, 2018, 25, 57-70.	1.2	34
98	Association of Cerebral Amyloid- $\hat{l}^2$ Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
99	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	10.2	195
100	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Neurobiology of Aging, 2018, 62, 245.e1-245.e7.	3.1	16
101	P1â€280: CEREBROSPINAL FLUID Aβ42 AND TAU MEASUREMENT ON LUMIPULSE® G: ANALYTICAL VERIFICATIC AND METHOD COMPARISON. Alzheimer's and Dementia, 2018, 14, P390.	)N <sub>0.8</sub>	0
102	Adenosine Deaminase Two and Immunoglobulin M Accurately Differentiate Adult Sneddon's Syndrome of Unknown Cause. Cerebrovascular Diseases, 2018, 46, 257-264.	1.7	15
103	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	2.6	12
104	The neural basis of fatigue in multiple sclerosis. Neurology: Clinical Practice, 2018, 8, 492-500.	1.6	18
105	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of $\hat{Al^2}$ species. NeuroImage: Clinical, 2018, 20, 603-610.	2.7	11
106	Addition of the AÎ <sup>2</sup> 42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. Alzheimer's Research and Therapy, 2018, 10, 33.	6.2	63
107	Using the Rasch analysis for the psychometric validation of the Irregular Word Reading Test (TeLPI): A Portuguese test for the assessment of premorbid intelligence. Clinical Neuropsychologist, 2018, 32, 60-76.	2.3	2
108	Validity and Clinical Utility of Different Clock Drawing Test Scoring Systems in Multiple Forms of Dementia. Journal of Geriatric Psychiatry and Neurology, 2018, 31, 114-122.	2.3	12

#	Article	IF	CITATIONS
109	The Head Turning Sign in Dementia and Mild Cognitive Impairment: Its Relationship to Cognition, Behavior, and Cerebrospinal Fluid Biomarkers. Dementia and Geriatric Cognitive Disorders, 2018, 46, 42-49.	1.5	6
110	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	3.1	15
111	The free and cued selective reminding test for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: A prospective longitudinal study. Journal of Neuropsychology, 2017, 11, 40-55.	1.4	13
112	Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients. Neuroscience Letters, 2017, 641, 101-106.	2.1	14
113	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	2.6	10
114	The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study. Alzheimer's and Dementia, 2017, 13, 1013-1023.	0.8	33
115	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. Acta Neuropathologica, 2017, 134, 475-487.	7.7	53
116	Disconnection as a mechanism for social cognition impairment in multiple sclerosis. Neurology, 2017, 89, 38-45.	1.1	43
117	Transthyretin stability is critical in assisting beta amyloid clearance– Relevance of transthyretin stabilization in Alzheimer's disease. CNS Neuroscience and Therapeutics, 2017, 23, 605-619.	3.9	38
118	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	3.1	27
119	Impairment of social cognition in multiple sclerosis: Amygdala atrophy is the main predictor. Multiple Sclerosis Journal, 2017, 23, 1358-1366.	3.0	55
120	<i>TBK1</i> Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	2.5	87
121	Clinical Reasoning: A 55-year-old man with rapidly progressive dementia and parkinsonism. Neurology, 2017, 89, e182-e187.	1.1	1
122	The Influence of Adipose Tissue on Brain Development, Cognition, and Risk of Neurodegenerative Disorders. Advances in Neurobiology, 2017, 19, 151-161.	1.8	10
123	[P4–189]: SYMPTOM ONSET IN GENETIC FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1337.	0.8	2
124	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	3.1	12
125	[P3–111]: NOVEL CANDIDATE GENES FOR DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2017, 13 P977.	8.o <sup>8</sup>	O
126	Predicting progression of mild cognitive impairment to dementia using neuropsychological data: a supervised learning approach using time windows. BMC Medical Informatics and Decision Making, 2017, 17, 110.	3.0	33

#	Article	IF	CITATIONS
127	Prognosis of Early-Onset vs. Late-Onset Mild Cognitive Impairment: Comparison of Conversion Rates and Its Predictors. Geriatrics (Switzerland), 2016, 1, 11.	1.7	38
128	Prosopagnosia as the Presenting Symptom of Whipple Disease. Cognitive and Behavioral Neurology, 2016, 29, 100-106.	0.9	6
129	Neuroimaging Correlates of Frontotemporal Dementia Associated with SQSTM1 Mutations. Journal of Alzheimer's Disease, 2016, 53, 303-313.	2.6	8
130	Portuguese family with the co-occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. Neurobiology of Aging, 2016, 41, 200.e1-200.e5.	3.1	96
131	Characterization of an FTLD-PDB family with the coexistence of SQSTM1 mutation and hexanucleotide (G 4 C 2 ) repeat expansion in C9orf72 gene. Neurobiology of Aging, 2016, 40, 191.e1-191.e8.	3.1	11
132	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- $\hat{l}^2$ in a multicentre European memory clinic study. Brain, 2016, 139, 2540-2553.	7.6	107
133	Three-Dimensional Face Recognition in Mild Cognitive Impairment: A Psychophysical and Structural MR Study. Journal of the International Neuropsychological Society, 2016, 22, 744-754.	1.8	6
134	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. Neurobiology of Aging, 2016, 46, 235.e1-235.e9.	3.1	37
135	Construct and diagnostic validities of the Free and Cued Selective Reminding Test in the Alzheimer's disease spectrum. Journal of Clinical and Experimental Neuropsychology, 2016, 38, 913-924.	1.3	3
136	MicroRNA deregulation and chemotaxis and phagocytosis impairment inÂAlzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 7-17.	2.4	51
137	Selective Reminding and Free and Cued Selective Reminding in Mild Cognitive Impairment and Alzheimer Disease. Applied Neuropsychology Adult, 2016, 23, 85-93.	1.2	7
138	Rare Variants in <i>PLD3 </i> Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. Human Mutation, 2015, 36, 1226-1235.	2.5	23
139	Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels inÂPatients with Alzheimer's Disease?. Journal of Alzheimer's Disease, 2015, 47, 1069-1078.	2.6	28
140	<scp>F</scp> ree and <scp>C</scp> ued <scp>S</scp> elective <scp>R</scp> eminding <scp>T</scp> est is superior to the <scp>W</scp> echsler <scp>M</scp> emory <scp>S</scp> cale in discriminating mild cognitive impairment from <scp>A</scp> lzheimer's disease. Geriatrics and Gerontology International, 2015, 15, 961-968.	1.5	9
141	The Relevance of Sociodemographic and Health Variables on MMSE Normative Data. Applied Neuropsychology Adult, 2015, 22, 311-319.	1.2	56
142	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	7.6	284
143	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiology of Aging, 2015, 36, 2005.e15-2005.e22.	3.1	34
144	Genetic Variation of <b><i>MT-ND</i></b> Genes in Frontotemporal Lobar Degeneration: Biochemical Phenotype-Genotype Correlation. Neurodegenerative Diseases, 2015, 15, 70-80.	1.4	1

9

#	Article	IF	Citations
145	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
146	Scaling Cognitive Domains of the Montreal Cognitive Assessment: An Analysis Using the Partial Credit Model. Archives of Clinical Neuropsychology, 2015, 30, 435-447.	0.5	13
147	Oxidative stress involving changes in Nrf2 and ER stress in early stages of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1428-1441.	3.8	137
148	Cerebrospinal fluid $\hat{Al}^240$ is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease. Journal of the Neurological Sciences, 2015, 358, 308-316.	0.6	25
149	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology, 2015, 11, 41-55.	10.1	144
150	The Portuguese version of Addenbrooke's Cognitive Examination–Revised (ACE-R) in the diagnosis of subcortical vascular dementia and Alzheimer's disease. Aging, Neuropsychology, and Cognition, 2015, 22, 473-485.	1.3	15
151	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.8	56
152	The free and cued selective reminding test: Validation for mild cognitive impairment and <scp>A</scp> lzheimer's disease. Journal of Neuropsychology, 2015, 9, 242-257.	1.4	43
153	Biparietal variant of Alzheimer's disease: a rare presentation of a common disease. BMJ Case Reports, 2015, 2015, bcr2014207011-bcr2014207011.	0.5	4
154	Severe post-influenza (H1N1) encephalitis involving pulvinar nuclei in an adult patient: FigureÂ1. BMJ Case Reports, 2015, 2015, bcr2015212667.	0.5	6
155	Progranulin Peripheral Levels as a Screening Tool for the Identification of Subjects with Progranulin Mutations in a Portuguese Cohort. Neurodegenerative Diseases, 2014, 13, 214-223.	1.4	28
156	Frontotemporal dementia: neuroanatomical correlates of an atypical presentation. BMJ Case Reports, 2014, 2014, bcr2014205089-bcr2014205089.	0.5	3
157	Obesity as a risk factor for Alzheimer's disease: the role of adipocytokines. Metabolic Brain Disease, 2014, 29, 563-568.	2.9	69
158	The Free and Cued Selective Reminding Test Distinguishes Frontotemporal Dementia From Alzheimer's Disease. Archives of Clinical Neuropsychology, 2014, 29, 670-679.	0.5	50
159	Psychometric Properties of the Montreal Cognitive Assessment (MoCA): An Analysis Using the Rasch Model. Clinical Neuropsychologist, 2014, 28, 65-83.	2.3	36
160	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	7.7	93
161	Premorbid IQ Influence on Screening Tests' Scores in Healthy Patients and Patients With Cognitive Impairment. Journal of Geriatric Psychiatry and Neurology, 2013, 26, 117-126.	2.3	30
162	Do MCI patients with vitamin B12 deficiency have distinctive cognitive deficits?. BMC Research Notes, 2013, 6, 357.	1.4	8

#	Article	IF	CITATIONS
163	A Panâ€ <scp>E</scp> uropean Study of the <i>C9orf72</i> Repeat Associated with <scp>FTLD</scp> : Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373.	2.5	247
164	Prediction of Long-Term (5 Years) Conversion to Dementia Using Neuropsychological Tests in a Memory Clinic Setting. Journal of Alzheimer's Disease, 2013, 34, 681-689.	2.6	21
165	The Clock Drawing Test: Portuguese Norms, by Age and Education, for Three Different Scoring Systems. Archives of Clinical Neuropsychology, 2013, 28, 375-387.	0.5	22
166	Impaired Processing of 3D Motion-Defined Faces in Mild Cognitive Impairment and Healthy Aging: An fMRI Study. Cerebral Cortex, 2013, 23, 2489-2499.	2.9	31
167	Montreal Cognitive Assessment. Alzheimer Disease and Associated Disorders, 2013, 27, 37-43.	1.3	356
168	TeLPI Performance in Subjects With Mild Cognitive Impairment and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2013, 27, 324-329.	1.3	5
169	Differences between Early and Late-Onset Alzheimer's Disease in Neuropsychological Tests. Frontiers in Neurology, 2012, 3, 81.	2.4	51
170	Multiple Dural Arteriovenous Fistulas Presenting as Rapidly Progressive Dementia. Neurologist, 2012, 18, 130-132.	0.7	17
171	Construct Validity of the Montreal Cognitive Assessment (MoCA). Journal of the International Neuropsychological Society, 2012, 18, 242-250.	1.8	124
172	Montreal Cognitive Assessment (MoCA): Validation Study for Vascular Dementia. Journal of the International Neuropsychological Society, 2012, 18, 1031-1040.	1.8	108
173	Montreal Cognitive Assessment: Influence of Sociodemographic and Health Variables. Archives of Clinical Neuropsychology, 2012, 27, 165-175.	0.5	93
174	Transthyretin Decrease in Plasma of MCI and AD Patients: Investigation of Mechanisms for Disease Modulation. Current Alzheimer Research, 2012, 9, 881-889.	1.4	48
175	Temporal Integration of 3D Coherent Motion Cues Defining Visual Objects of Unknown Orientation is Impaired in Amnestic Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 885-896.	2.6	18
176	Comparison of Four Verbal Memory Tests for the Diagnosis and Predictive Value of Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders Extra, 2012, 2, 120-131.	1.3	55
177	Amyloid $\hat{I}^2$ -induced ER stress is enhanced under mitochondrial dysfunction conditions. Neurobiology of Aging, 2012, 33, 824.e5-824.e16.	3.1	72
178	Exome sequencing reveals an unexpected genetic cause of disease: NOTCH3 mutation in a Turkish family with Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1008.e17-1008.e23.	3.1	86
179	Serial position effects in Alzheimer's disease, mild cognitive impairment, and normal aging: Predictive value for conversion to dementia. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 841-852.	1.3	35
180	Montreal Cognitive Assessment (MoCA): Validation study for Frontotemporal Dementia. Journal of Geriatric Psychiatry and Neurology, 2012, 25, 146-154.	2.3	66

#	Article	IF	CITATIONS
181	Montreal Cognitive Assessment (MoCA): Normative study for the Portuguese population. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 989-996.	1.3	242
182	Data mining methods in the prediction of Dementia: A real-data comparison of the accuracy, sensitivity and specificity of linear discriminant analysis, logistic regression, neural networks, support vector machines, classification trees and random forests. BMC Research Notes, 2011, 4, 299.	1.4	284
183	Validation studies of the Portuguese experimental version of the Montreal Cognitive Assessment (MoCA): confirmatory factor analysis. Journal of Neurology, 2010, 257, 728-734.	3.6	79
184	Oxidative Damage and Progression to Alzheimer's Disease in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 21, 1165-1177.	2.6	78
185	Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiology of Aging, 2010, 31, 725-731.	3.1	196
186	Genetic Variability in CLU and Its Association with Alzheimer's Disease. PLoS ONE, 2010, 5, e9510.	2.5	52
187	Sporadic Creutzfeldt-Jakob Disease Causing a 2-Years Slowly Progressive Isolated Dementia. Behavioural Neurology, 2009, 21, 175-179.	2.1	1
188	Cognitive deficits in middleâ€aged and older adults with bipolar disorder and cognitive complaints: Comparison with mild cognitive impairment. International Journal of Geriatric Psychiatry, 2009, 24, 624-631.	2.7	11
189	Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients. Journal of Neurology, 2009, 256, 1540-1550.	3.6	48
190	Novel progranulin mutation: Screening for PGRN mutations in a Portuguese series of FTD/CBS cases. Movement Disorders, 2008, 23, 1269-1273.	3.9	30
191	Adaptive visual memory reorganization in right medial temporal lobe epilepsy. Epilepsia, 2008, 49, 1395-1408.	5.1	19
192	Peripheral Oxidative Damage in Mild Cognitive Impairment and Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 15, 117-128.	2.6	133
193	Peripheral Inflammatory Cytokines as Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment. Neurodegenerative Diseases, 2007, 4, 406-412.	1.4	135
194	Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurology, 2006, 6, 24.	1.8	78
195	Mitochondrial DNA Variants in a Portuguese Population of Patients with Alzheimer's Disease. European Neurology, 2005, 53, 121-124.	1.4	9
196	Mitochondria dysfunction of Alzheimer's disease cybrids enhances $\hat{Al^2}$ toxicity. Journal of Neurochemistry, 2004, 89, 1417-1426.	3.9	258
197	Frontotemporal dementia and mitochondrial DNA transitions. Neurobiology of Disease, 2004, 15, 306-311.	4.4	12
198	Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiology of Aging, 2004, 25, 105-110.	3.1	266

#	Article	IF	CITATIONS
199	Exome Sequencing of a Portuguese Cohort of Frontotemporal Dementia Patients: Looking Into the ALS-FTD Continuum. Frontiers in Neurology, $0,13,.$	2.4	2